Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Pulmonary Embolism As An Adverse Drug Event Of Intravenous Immunoglobulin Therapy, Katasha S. Butler, Deborah S. Zeitlin
Pulmonary Embolism As An Adverse Drug Event Of Intravenous Immunoglobulin Therapy, Katasha S. Butler, Deborah S. Zeitlin
Deborah Zeitlin
TO THE EDITOR: Intravenous immunoglobulin (IVIG) therapy has gained popularity for the treatment of neuromuscular diseases (i.e., myasthenia gravis, inflammatory myopathy, chronic inflammatory demyelinating polyneuropathy), although adverse events are associated with high-dose IVIG infusions.1,2 Common adverse reactions to IVIG therapy are anxiety, headache, fever, chills, chest pain, dyspnea, nausea, and abdominal pain.3 More serious adverse events include anaphylaxis, hemolytic anemia, hepatitis C, and thrombosis.3 Studies have shown documented effects of IVIG on blood rheology. It increases plasma viscosity in a dose-related response and may also activate platelets.2–4 High-dose IVIG therapy is approximately 24–54 g/d.4
Pulmonary Embolism As An Adverse Drug Event Of Intravenous Immunoglobulin Therapy, Katasha S. Butler, Deborah S. Zeitlin
Pulmonary Embolism As An Adverse Drug Event Of Intravenous Immunoglobulin Therapy, Katasha S. Butler, Deborah S. Zeitlin
Deborah Zeitlin
TO THE EDITOR: Intravenous immunoglobulin (IVIG) therapy has gained popularity for the treatment of neuromuscular diseases (i.e., myasthenia gravis, inflammatory myopathy, chronic inflammatory demyelinating polyneuropathy), although adverse events are associated with high-dose IVIG infusions.1,2 Common adverse reactions to IVIG therapy are anxiety, headache, fever, chills, chest pain, dyspnea, nausea, and abdominal pain.3 More serious adverse events include anaphylaxis, hemolytic anemia, hepatitis C, and thrombosis.3 Studies have shown documented effects of IVIG on blood rheology. It increases plasma viscosity in a dose-related response and may also activate platelets.2–4 High-dose IVIG therapy is approximately 24–54 g/d.4